Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-An update on patient populations with a wide range of cardiovascular risk

Pharmacological Research

Volumn 60, Issue 6, 2009, Pages 481-487

  Böger, Rainer H ^a   Maas, Renke ^b   Schulze, Friedrich ^a   Schwedhelm, Edzard ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cardiovascular disease; Endothelium; Nitric oxide; Risk markers

Indexed keywords

ARGININE; C REACTIVE PROTEIN; FIBRINOGEN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UNSTABLE ANGINA PECTORIS;

ANIMALS; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 70350057304     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.07.001     Document Type: Review

References (61)

1. Bedford M.T., and Clarke S.G. Protein arginine methylation in mammals: who, what, and why. Mol Cell 33 (2009) 1-13
2. Nicholson T., Chen T., and Richard S. The role of protein arginine methylation in normal and diseased cells. Pharmacol Res 60 (2009) 466-474
3. Ogawa T., Kimoto M., and Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 264 (1989) 10205-10209
4. Kimoto M., Whitley G.S., Tsuji H., and Ogawa T. Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem 117 (1995) 237-238
5. Leiper J.M., Santa Maria J., Chubb A., MacAllister R.J., Charles I.G., Whitley G.S., et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343 (1999) 209-214
6. Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: Regulation and action. Phamracol Res; in press.
7. Böger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38 (2006) 126-136
8. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., and Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99 (1999) 3092-3095
9. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
10. Kielstein J.T., Böger R.H., Bode-Böger S.M., Schäffer J., Barbey M., Koch K.M., et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10 (1999) 594-600
11. Fliser D., Kronenberg F., Kielstein J.T., Morath C., Bode-Böger S.M., Haller H., et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 16 (2005) 2456-2461
12. Foley R.N., Parfrey P.S., and Sarnak M.J. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9 (1998) S16-S23
13. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiological perspective. Kidney Int 70 (2006) 26-33
14. Zoccali C., Bode-Böger S.M., Mallamaci F., Benedetto F.A., Tripepi G., Malatino L., et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet 358 (2001) 2113-2117
15. Ravani P., Tripepi G., Malberti F., Testa S., Mallamaci F., and Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16 (2005) 2449-2455
16. Kumagai H., Sakurai M., Takita T., Maruyama Y., Uno S., Ikegaya N., et al. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Am J Kidney Dis 48 (2006) 797-805
17. Young J.M., Terrin N., Wang X., Greene T., Beck G.J., Kusek J.W., et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 4 (2009) 1115-1120
18. Busch M., Fleck C., Wolf G., and Stein G. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease-possible candidates for paradoxical epidemiology?. Amino Acids 30 (2006) 225-232
19. Nijveldt R.J., Teerlink T., Van Der Hoven B., Siroen M.P., Kuik D.J., Rauwerda J.A., et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 22 (2003) 23-30
20. Lee T.H., Marcantonio E.R., Mangione C.M., Thomas E.J., Polanczyk C.A., Cook E.F., et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 100 (1999) 1043-1049
21. Maas R., Dentz L., Schwedhelm E., Thoms W., Kuss O., Hiltmeyer N., et al. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) predict adverse events in patients undergoing noncardiac surgery. Crit Care Med 35 (2007) 1876-1881
22. Krempl T.K., Kähler J., Maas R., Silberhorn L., Meinertz T., and Böger R.H. Elevation of asymmetric dimethylarginine (ADMA) in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 26 (2005) 1846-1851
23. Cavusoglu E., Ruwende C., Chopra V., Yanamadala S., Eng C., Pinsky D.J., et al. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography. Coron Artery Dis 20 (2009) 112-117
24. Schulze F., Vollert J., Maas R., Müller R., Schwedhelm E., Müller C., et al. Asymmetric dimethylarginine predicts outcome and time of stay in hospital in patients attending an internal medicine emergency room. Clin Chim Acta 401 (2009) 20-24
25. Lu T.M., Ding Y.A., Lin S.J., Lee W.S., and Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 24 (2003) 1912-1919
26. Schnabel R., Blankenberg S., Lubos E., Lackner K.J., Rupprecht H.J., Espinola-Klein C., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97 (2005) e53-e59
27. Meinitzer A., Seelhorst U., Wellnitz B., Halwachs-Baumann G., Boehm B.O., Winkelmann B.R., et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 53 (2007) 273-283
28. Weil J., Schulz K., Schüler H., Schwedhelm E., Graf T., Boger R.H., et al. Elevated plasma level of asymmetric dimethylarginine (ADMA) is a predictor of total mortality in patients presenting with acute myocardial infarction. Circulation 118 (2008) S1103
29. Zeller M., Korandji C., Guilland J.C., Sicard P., Vergely C., Lorgis L., et al. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol 28 (2008) 954-960
30. Zoccali C., Mallamaci F., Maas R., Benedetto F.A., Tripepi G., Malatino L.S., et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62 (2002) 339-345
31. Dückelmann C., Mittermayer F., Haider D.G., Altenberger J., Eichinger J., and Wolzt M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 27 (2007) 2037-2042
32. Mittermayer F., Krzyzanowska K., Exner M., Mlekusch W., Amighi J., Sabeti S., et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 26 (2006) 2536-2540
33. Kielstein J.T., Bode-Böger S.M., Hesse G., Martens-Lobenhoffer J., Takacs A., Fliser D., et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 25 (2005) 1414-1418
34. Krzyzanowska K., Mittermayer F., Wolzt M., and Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 30 (2007) 1834-1839
35. Lajer M., Tarnow L., Jorsal A., Teerlink T., Parving H.H., and Rossing P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 31 (2008) 747-752
36. Wanby P., Teerlink T., Brudin L., Brattström L., Nilsson I., Palmqvist P., et al. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 185 (2006) 271-277
37. Kielstein J.T., Donnerstag F., Gasper S., Menne J., Kielstein A., Martens-Lobenhoffer J., et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37 (2006) 2024-2029
38. Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 10 Suppl. 1 (2005) S89-S91
39. Valkonen V.P., Päivä H., Salonen J.T., Lakka T.A., Lehtimäki T., Laakso J., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
40. Maas R., Schulze F., Baumert J., Löwel H., Hamraz K., Schwedhelm E., et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based monitoring of trends and determinants in cardiovascular disease/Kooperative Gesundheitsforschung in der Region Augsburg Study and experimental data. Clin Chem 53 (2007) 693-701
41. Leong T., Zylberstein D., Graham I., Lissner L., Ward D., Fogarty J., et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 28 (2008) 961-967
42. Conroy R.M., Pyörälä K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24 (2003) 987-1003
43. Kannel W.B., Feinleib M., McNamara P.M., Garrison R.J., and Castelli W.P. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol 110 (1979) 281-290
44. Böger R.H., Sullivan L.M., Schwedhelm E., Wang T.J., Maas R., Benjamin E.J., et al. Plasma asymmetric dimethylarginine (ADMA) and incidence of cardiovascular disease and mortality in the community. Circulation 119 (2009) 1592-1600
45. Morris C.R. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program 2008 (2008) 177-185
46. Ryoo S., Gupta G., Benjo A., Lim H.K., Camara A., Sikka G., et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 102 (2008) 923-932
47. Jacobi J., Sydow K., von Degenfeld G., Zhang Y., Dayoub H., Wang B., et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 111 (2005) 1431-1438
48. Kostourou V., Robinson S.P., Cartwright J.E., and Whitley G.S. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer 87 (2002) 673-680
49. Schulze F., Maas R., Freese R., Schwedhelm E., Silberhorn L., and Böger R.H. Determination of a reference value for N,N-dimethyl-l-arginine in 500 subjects. Eur J Clin Invest 35 (2005) 622-626
50. Teerlink T. HPLC analysis of ADMA and other methylated l-arginine analogs in biological fluids. J Chromatogr B Anal Technol Biomed Life Sci 851 (2007) 21-29
51. Schwedhelm E, Xanthakis V, Maas R, Sullivan LM, Schulze F, Riederer U, et al. Asymmetric dimethylarginine reference intervals determined with tandem mass spectrometry-liquid chromatography: results from the Framingham Offspring cohort. Clin Chem; in press.
52. Hlatky M.A., Greenland P., Arnett D.K., Ballantyne C.M., Criqui M.H., Elkind M.S., et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119 (2009) 2408-2416
53. Schulze F., Wesemann R., Schwedhelm E., Sydow K., Albsmeier J., Cooke J.P., et al. Determination of ADMA using a novel ELISA assay. Clin Chem Lab Med 42 (2004) 1377-1383
54. Schwedhelm E., Maas R., Tan-Andresen J., Schulze F., Riederer U., and Böger R.H. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B 851 (2007) 211-219
55. Sydow K., Schwedhelm E., Arakawa N., Bode-Böger S.M., Tsikas D., Hornig B., et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia. Effects of l-arginine and B vitamins. Cardiovasc Res 57 (2003) 244-252
56. Schulman S.P., Becker L.C., Kass D.A., Champion H.C., Terrin M.L., Forman S., et al. l-arginine therapy in acute myocardial infarction: the Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 295 (2006) 58-64
57. Wilson A.M., Harada R., Nair N., Balasubramanian N., and Cooke J.P. l-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 116 (2007) 188-195
58. Bednarz B., Jaxa-Chamiec T., Maciejewski P., Szpajer M., Janik K., Gniot J., et al. Efficacy and safety of oral l-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol 62 (2005) 421-427
59. Dayoub H., Achan V., Adimoolam S., Jacobi J., Stuehlinger M.C., Wang B.Y., et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108 (2003) 3042-3047
60. Leiper J., Nandi M., Torondel B., Murray-Rust J., Malaki M., O'Hara B., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 13 (2007) 198-203
61. Kotthaus J., Schade D., Muschick N., Beitz E., and Clement B. Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem 16 (2008) 10205-10209